PCI策略在心源性休克患者中的一年结局
该研究为随机对照试验,纳入706例急性心肌梗死合并心源性休克及多支冠状动脉病变患者,随机分为仅罪犯病变PCI组和立即多支PCI组。既往已报告30天主要终点(死亡或肾脏替代治疗)在仅罪犯病变PCI组为45.9%,多支PCI组为55.4%(P=0.01)。1年随访时,仅罪犯病变PCI组死亡172/344例(50.0%),多支PCI组194/341例(56.9%),相对风险0.88(95%CI 0.76-1.01),无显著差异。仅罪犯病变PCI组再次血运重建(32.3% vs 9.4%,RR 3.44)和因心力衰竭再住院(5.2% vs 1.2%,RR 4.46)更频繁。
要点
- 30天主要终点(死亡或肾脏替代治疗):仅罪犯病变PCI组45.9% vs 多支PCI组55.4%(P=0.01)。
- 1年死亡:仅罪犯病变PCI组50.0%(172/344) vs 多支PCI组56.9%(194/341),RR 0.88(95%CI 0.76-1.01),无显著差异。
- 1年再次血运重建:仅罪犯病变PCI组32.3% vs 多支PCI组9.4%,RR 3.44(95%CI 2.39-4.95)。
- 1年因心衰再住院:仅罪犯病变PCI组5.2% vs 多支PCI组1.2%,RR 4.46(95%CI 1.53-13.04)。
- 1年死亡或再发心梗复合终点:仅罪犯病变PCI组50.9% vs 多支PCI组58.4%,RR 0.87(95%CI 0.76-1.00)。
适用人群与场景
- 急性心肌梗死合并心源性休克及多支冠状动脉病变的患者,随机接受仅罪犯病变PCI或立即多支PCI。
处置流程与药物剂量
- 仅罪犯病变PCI:仅对罪犯病变行经皮冠状动脉介入治疗。
- 立即多支PCI:对多支冠状动脉病变行立即经皮冠状动脉介入治疗。
研究设计与关键结果
- 随机对照试验,706例患者随机分为仅罪犯病变PCI组或多支PCI组;30天主要终点(死亡或肾脏替代治疗)仅罪犯病变PCI组45.9% vs 多支PCI组55.4%(P=0.01)。
- 1年死亡:仅罪犯病变PCI组50.0%(172/344) vs 多支PCI组56.9%(194/341),RR 0.88(95%CI 0.76-1.01)。
- 1年再发心梗:仅罪犯病变PCI组1.7% vs 多支PCI组2.1%,RR 0.85(95%CI 0.29-2.50)。
- 1年死亡或再发心梗复合终点:仅罪犯病变PCI组50.9% vs 多支PCI组58.4%,RR 0.87(95%CI 0.76-1.00)。
- 1年再次血运重建:仅罪犯病变PCI组32.3% vs 多支PCI组9.4%,RR 3.44(95%CI 2.39-4.95)。
- 1年因心衰再住院:仅罪犯病变PCI组5.2% vs 多支PCI组1.2%,RR 4.46(95%CI 1.53-13.04)。
证据类型、等级与局限
- 证据类型:随机对照试验(CULPRIT-SHOCK,NCT01927549)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急性心肌梗死合并心源性休克及多支冠状动脉病变的患者,仅罪犯病变PCI较立即多支PCI降低30天死亡或肾脏替代治疗风险。
- 1年随访时两组死亡率无显著差异,但仅罪犯病变PCI组再次血运重建和因心衰再住院更频繁。
指南或共识出处
- CULPRIT-SHOCK试验(ClinicalTrials.gov NCT01927549),由欧盟第七框架计划等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite of death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found to be lower with percutaneous coronary intervention (PCI) of the culprit lesion only than with immediate multivessel PCI. We evaluated clinical outcomes at 1 year.
METHODS: We randomly assigned 706 patients to either culprit-lesion-only PCI or immediate multivessel PCI. The results for the primary end point of death or renal-replacement therapy at 30 days have been reported previously. Prespecified secondary end points at 1 year included death from any cause, recurrent myocardial infarction, repeat revascularization, rehospitalization for congestive heart failure, the composite of death or recurrent infarction, and the composite of death, recurrent infarction, or rehospitalization for heart failure.
RESULTS: As reported previously, at 30 days, the primary end point had occurred in 45.9% of the patients in the culprit-lesion-only PCI group and in 55.4% in the multivessel PCI group (P=0.01). At 1 year, death had occurred in 172 of 344 patients (50.0%) in the culprit-lesion-only PCI group and in 194 of 341 patients (56.9%) in the multivessel PCI group (relative risk, 0.88; 95% confidence interval [CI], 0.76 to 1.01). The rate of recurrent infarction was 1.7% with culprit-lesion-only PCI and 2.1% with multivessel PCI (relative risk, 0.85; 95% CI, 0.29 to 2.50), and the rate of a composite of death or recurrent infarction was 50.9% and 58.4%, respectively (relative risk, 0.87; 95% CI, 0.76 to 1.00). Repeat revascularization occurred more frequently with culprit-lesion-only PCI than with multivessel PCI (in 32.3% of the patients vs. 9.4%; relative risk, 3.44; 95% CI, 2.39 to 4.95), as did rehospitalization for heart failure (5.2% vs. 1.2%; relative risk, 4.46; 95% CI, 1.53 to 13.04).
CONCLUSIONS: Among patients with acute myocardial infarction and cardiogenic shock, the risk of death or renal-replacement therapy at 30 days was lower with culprit-lesion-only PCI than with immediate multivessel PCI, and mortality did not differ significantly between the two groups at 1 year of follow-up. (Funded by the European Union Seventh Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).
参考来源
- Thiele H, Akin I, Sandri M, et al. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med. 2018. PMID: 30145971. doi:10.1056/NEJMoa1808788
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。